Show simple item record


Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes

dc.contributor.authorRuiz Rodríguez, Victor Manuel
dc.contributor.authorTuriján Espinoza, Eneida
dc.contributor.authorGuel Pañola, Jaime Arturo
dc.contributor.authorGarcía Hernández, Mariana Haydee
dc.contributor.authorZermeño Nava, José de Jesús
dc.contributor.authorLópez López, Nallely
dc.contributor.authorBernal Silva, Sofia
dc.contributor.authorLayseca Espinosa, Esther
dc.contributor.authorFuentes Pananá, Ezequiel Moises
dc.contributor.authorEstrada Sánchez, Ana María
dc.contributor.authorPortales Pérez, Diana Patricia
dc.identifier.citationRuiz-Rodríguez VM, Turiján-Espinoza E, Guel-Pañola JA, García Hernández MH, Zermeño Nava JDJ, López López N, Bernal-Silva S, Layseca-Espinosa E, Fuentes-Pananá EM, Estrada Sánchez AM and Portales Pérez DP (2020) Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes. Front. Pharmacol. 11:576955. doi: 10.3389/fphar.2020.576955
dc.description.abstract"Breast cancer (BRCA) is the most frequent cancer type that afflicts women. Unfortunately, despite all the current therapeutic strategies, many patients develop chemoresistance hampering the efficacy of treatment. Hence, an early indicator of therapy efficacy might aid in the search for better treatment and patient survival. Although emerging evidence indicates a key role of the purinergic receptors P2X7 and A2A in cancer, less is known about their involvement in BRCA chemoresistance. In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8+ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. The results showed an increase in the levels of expression of P2X7 and a decrease in the expression of A2A in CD8+ T cells in non-chemoresistant (N-CHR) patients, compared to chemoresistant (CHR) patients. Interestingly, in CHR patients, reduced expression of P2X7 occurs along with a decrease in the CD62L shedding and the production of IFN-?. In the case of the A2A function, the inhibition of IFN-? production was not observed after chemotherapy in CHR patients. A possible relationship between the modulation of the expression and function of the P2X7 and A2A receptors was found, according to the molecular subtypes, where the patients that were triple-negative and human epidermal growth factor receptor 2 (HER2)-enriched presented more alterations. Comorbidities such as overweight/obesity and type 2 diabetes mellitus (T2DM) participate in the abnormalities detected. Our results demonstrate the importance of purinergic signaling in CD8+ T cells during chemoresistance, and it could be considered to implement personalized therapeutic strategies."
dc.publisherFrontiers Media S.A.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.subjectP2X7 receptor
dc.subjectA2A receptor
dc.subjectCD8+ T cells
dc.titleChemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes
dc.rights.accessAcceso Abierto

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional